Drug Development and Industrial Pharmacy最新文献

{"title":"Development of a transdermal sumatriptan formulation with iontophoresis.","authors":"Kenji Mori, Takeshi Oshizaka, Kenji Sugibayashi","doi":"10.1080/03639045.2026.2692054","DOIUrl":"10.1080/03639045.2026.2692054","url":null,"abstract":"<p><strong>Objective: </strong>A transdermal iontophoretic formulation for sumatriptan was approved by the U.S. FDA in 2013 for patients who cannot take oral medications. However, it was withdrawn in 2020 due to skin burns and scarring associated with prolonged electrical applications. This study aimed to determine whether <i>short-duration, low-current iontophoresis</i> can still achieve therapeutically effective plasma concentrations of sumatriptan.</p><p><strong>Significance: </strong>Developing a safe, rapid-acting transdermal delivery system would provide an alternative treatment option for patients who cannot tolerate oral medications, while reducing the risk injury caused by long-term electrical exposure.</p><p><strong>Methods: </strong>The target plasma concentration in rats was calculated from rat elimination pharmacokinetics and previously reported human therapeutic concentrations. Rats received 0.04, 0.2, or 0.4% sumatriptan gel on the abdominal skin, and iontophoresis was applied at 0.05, 0.1, or 0.2 mA/cm² for 2 h. Plasma concentrations were measured over time. An additional experiment applied 0.2 mA/cm² for 0.5 h followed by 0.1 mA/cm² for 0.5 h.</p><p><strong>Results: </strong>Based on the maximal plasma concentration after oral administration in humans (16.5 ng/mL), the target plasma concentration in rats was calculated as 0.94 µg/mL. The 0.2 and 0.4% formulations at 0.1 mA/cm² exceeded this target within 1.5 and 1.0 h, respectively. The 0.2% formulation at 0.2 mA/cm² surpassed the target within 0.5 h and maintained it for 3 h.</p><p><strong>Conclusions: </strong><i>Short-duration, low-current iontophoresis</i> effectively achieved therapeutic plasma concentration of sumatriptan. These findings support the potential of this approach as a safer transdermal alternative for patients unable to take oral medications.</p>","PeriodicalId":11263,"journal":{"name":"Drug Development and Industrial Pharmacy","volume":" ","pages":"1612-1622"},"PeriodicalIF":2.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148270516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medium-chain fatty acid-enabled nanostructured lipid carriers for improved β-carotene biopharmaceutical properties and antioxidant efficacy.","authors":"Wan-Yi Liu, Ting-Wen Fu, Horng-Huey Ko, Li-Ching Chang, Yu-Tse Wu","doi":"10.1080/03639045.2026.2686852","DOIUrl":"10.1080/03639045.2026.2686852","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to enhance the <i>in vitro</i> digestion and permeability of β-carotene (BC), a lipophilic antioxidant with therapeutic potential in oxidative stress-related disorders, by developing a nanostructured lipid carrier (NLC) system based on medium-chain fatty acids (MCFAs).</p><p><strong>Significance: </strong>Although BC exhibits strong antioxidant activity, its poor solubility and low gastrointestinal absorption limit clinical use. This study addresses these barriers by formulating a novel medium-chain fatty acid-based NLC using ethanol injection method that improves BC's solubility, permeability, and bioactivity. The approach offers a scalable oral promising platform for antioxidant therapies targeting chronic diseases linked to oxidative stress.</p><p><strong>Methods: </strong>BC-loaded NLC (BC-NLC) was prepared <i>via</i> ethanol injection and subsequently optimized using a Box-Behnken design. Physicochemical properties, biopharmaceutical performance, and antioxidant effects were evaluated.</p><p><strong>Results: </strong>The optimized BC-NLC showed a particle size of 153.9 nm, polydispersity index of 0.29, zeta potential of -14.1 mV, and encapsulation efficiency of 62.0%. <i>In vitro</i> digestion revealed 63-fold and 38-fold increases in BC micellar efficiency in simulated gastric and intestinal fluids, respectively. A 9.1-fold enhancement in intestinal transport was observed. Stability testing confirmed >88% BC retention over 28 days at 5 °C. Antioxidant assays demonstrated ≥2.3-fold higher radical scavenging activity and a 22.7-fold increase in reducing power compared to free BC.</p><p><strong>Conclusions: </strong>The MCFAs-based BC-NLC effectively overcomes key biopharmaceutical limitations, offering enhanced <i>in vitro</i> digestion, stability, and antioxidant efficacy. It represents a promising oral delivery strategy for oxidative stress-related therapeutic applications.</p>","PeriodicalId":11263,"journal":{"name":"Drug Development and Industrial Pharmacy","volume":" ","pages":"1579-1593"},"PeriodicalIF":2.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148210527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and evaluation of a multifunctional natural composite microemulsion for anti-acne therapy: synergistic anti-inflammatory and antibacterial effects.","authors":"Siqi Rao, Ying Chen, Chunlin Tao, Jialing Chen, Huicai Wu, Wenjin Xu","doi":"10.1080/03639045.2026.2661824","DOIUrl":"10.1080/03639045.2026.2661824","url":null,"abstract":"<p><strong>Introduction: </strong>Acne is a common inflammatory disease of the hair follicles and sebaceous glands, but most of the current treatments have side effects or drug resistance problems. This study developed a stable, self-emulsifying composite Microemulsion (PHS-ME) co-loaded with paeonol, honokiol and Salix alba (white willow) bark extract.</p><p><strong>Methods: </strong>The formulation was optimized using Box-Behnken design. Physicochemical properties, centrifugation and storage stability (35 days at 4 °C, 25 °C, and 40 °C), <i>in vitro</i> drug release, cytotoxicity (HaCaT cells), cellular uptake, anti-inflammatory activity (LPS-stimulated RAW264.7 cells), and antibacterial efficacy against Cutibacterium acnes and Staphylococcus aureus were evaluated.</p><p><strong>Results: </strong>PHS-ME exhibited a uniform spherical morphology with a mean droplet size of 13.54 ± 0.35 nm, high encapsulation efficiency, and excellent physical stability. It showed sustained drug release, good biocompatibility (safe up to 8 µg/mL). Finally, PHS-ME significantly enhanced the cellular uptake of HaCaT and effectively inhibited the production of key inflammatory mediators in RAW264.7. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) values of the composite Microemulsion against <i>Cutibacterium acnes</i> and <i>Staphylococcus aureus</i> for acne were the same, which were 0.5 mg/mL and 2 mg/mL respectively.</p><p><strong>Discussion: </strong>This study proposes a simple and stable strategy for preparing composite Microemulsion. Due to its synergistic anti-inflammatory and antibacterial properties, these Microemulsions have great industrial potential as a natural local anti-acne product.</p>","PeriodicalId":11263,"journal":{"name":"Drug Development and Industrial Pharmacy","volume":" ","pages":"1291-1306"},"PeriodicalIF":2.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147721985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A review on artificial intelligence in pharmaceutical sciences: opportunities and challenges.","authors":"Vivek Kumar, Saurav Kumar, Ravi Kumar, Nidhi Tiwari, Jeetendra Kumar Gupta","doi":"10.1080/03639045.2026.2670435","DOIUrl":"10.1080/03639045.2026.2670435","url":null,"abstract":"<p><strong>Significance: </strong>The review aims to systematically explore the transformative impact of artificial intelligence (AI) on pharmaceutical sciences. It addresses key research questions regarding how AI accelerates drug development, enhances clinical trial design, optimizes manufacturing, and drives advances in personalized and precision medicine.</p><p><strong>Methods: </strong>A comprehensive literature review was conducted. It synthesized recent studies, industry reports, and regulatory guidelines on AI adoption. Covered drug discovery, clinical trials, pharmacovigilance, manufacturing, supply chain management, and pharmacy education. It also critically examined barriers such as data quality, privacy, explainability, and the evolving regulatory landscape.</p><p><strong>Results: </strong>AI accelerates pharmaceutical R&D, identification, lead optimization, ADMET (absorption, distribution, metabolism, excretion, toxicity) prediction, drug repurposing, and clinical trial analytics. It enables faster and more cost-effective development. Advancements in personalized medicine and individualized patient data are driving better patient outcomes. The students still ace continuing challenges in data interpretation, privacy, and regulatory issues.</p><p><strong>Conclusions: </strong>Ongoing AI advancements and evolving regulations are set to revolutionize pharmaceutical science. They will enable efficient, predictive, and patient-centered healthcare. Success will depend on integrating multi-omics, adopting explainable AI, and fostering collaboration among all stakeholders. Ultimately, AI promises safer, faster, and more precise drug delivery system. It benefits clinicians, researchers, and students.</p>","PeriodicalId":11263,"journal":{"name":"Drug Development and Industrial Pharmacy","volume":" ","pages":"1220-1250"},"PeriodicalIF":2.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147867104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Formulation and optimization of venlafaxine loaded nanostructure lipid carrier based intranasal drug delivery system for brain targeting through <i>in vivo</i> study.","authors":"Sulekha Khute, Subash Paranthaman, Rajendra Kumar Jangde","doi":"10.1080/03639045.2026.2667238","DOIUrl":"10.1080/03639045.2026.2667238","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to develop and optimize nanostructured lipid carriers (NLCs) to deliver venlafaxine (VLF) intranasally to optimize its brain bioavailability.</p><p><strong>Significance: </strong>The present study explores the development of an intranasal nanostructured lipid carrier-based drug delivery system for brain targeting of venlafaxine. Intranasal administration provides a noninvasive pathway for direct drug transport to the brain through the olfactory and trigeminal pathways, potentially bypassing the blood-brain barrier. Designing venlafaxine-loaded NLCs will help to increase the stability of drugs, increase the nasal residence time and provide an efficient method of delivering drugs to the brain, which is one of the promising measures toward the better treatment of depressive disorders.</p><p><strong>Methods: </strong>VLF-loaded NLCs were prepared <i>via</i> high-pressure homogenization and optimized using the Box-Behnken design. Glycerol monostearate and olive oil were used as lipid matrices, and Tween 80 was used as a surfactant. The physicochemical properties (particle size 112.99 nm, zeta potential -20.85 ± 2.27 mV, entrapment efficiency 94.89 ± 0.27%, drug loading 5.76 ± 0.12%) of the nanoparticles, including particle size, zeta potential, and entrapment efficiency were evaluated. <i>In vitro</i> release studies were conducted, followed by <i>in vivo</i> assessments of brain-targeting efficiency using drug-concentration analysis in brain tissues.</p><p><strong>Results: </strong>The optimized VLF-loaded NLCs showed a particle size of 112.99 nm, zeta potential of 15.21 + 3.11 mV as well as drug entrapment efficiency of 94.89%. <i>In vitro</i> release showed a biphasic release profile (an initial burst release (39.7 + 0.01% in 2 h)) and a sustained release (94.56 + 1.2% in 24 h). The results of the <i>in vivo</i> experiments showed a significant increase in VLF concentrations in the brain tissues following administration through the intranasal route compared to administration through the oral route, and a 2.15-fold increase in Cmax, 22.5-fold larger Area Under Curve (AUC 0-), and a 9.2-h delay in Tmax (<i>p</i> < 0.05), indicating improved brain-targeting.</p><p><strong>Conclusion: </strong>The intranasal NLC system developed was able to increase the bioavailability and brain delivery of VLF with the drawback of the oral route avoided. The biphasic release profile favors the lasting therapeutic activity. This method opens a good platform of CNS drug delivery that should be pursued by additional pharmacokinetic and clinical research.</p>","PeriodicalId":11263,"journal":{"name":"Drug Development and Industrial Pharmacy","volume":" ","pages":"1321-1337"},"PeriodicalIF":2.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148041530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Formulation and optimization of <i>Dryopteris cochleata</i> extract-laden liposomes for immunostimulant activity in rats: <i>in vitro</i> and <i>in vivo</i> evaluation.","authors":"Shubhangi Patil, Popat Kumbhar, Rajnandini Patil, Sakshi Mane, Sameer Nadaf, Mansingraj Nimbalkar, Ashok Wali, Shailendra Gurav, John Disouza","doi":"10.1080/03639045.2026.2660831","DOIUrl":"10.1080/03639045.2026.2660831","url":null,"abstract":"<p><strong>Objective: </strong>This study sought to develop <i>Dryopteris cochleata</i> (DC) extract encapsulated liposomes and their characterization in order to increase its immunomodulatory activity.</p><p><strong>Significance: </strong>The significance of <i>DC</i> extract-laden liposomes is to improve their immunostimulant activity. Thus, this technology offers a novel immunotherapeutic strategy to combat a range of diseases.</p><p><strong>Methods: </strong><i>DC</i> extract was obtained using supercritical fluid extraction and screened for acute oral toxicity in Wistar rats. The extract-laden liposomes were optimized by Box-Behnken Design (BBD) and were evaluated for different <i>in vitro</i> parameters. Moreover, extract and liposomes were investigated for immunomodulatory activity in Wistar albino rats.</p><p><strong>Results: </strong>The extract was found to be safe in Wistar rats at a dose of 2000 mg/kg. The optimized liposomes fabricated with phosphatidylcholine (4.5 mg) and cholesterol (3.1 mg), and probe cycle number of 56.5, displayed particle size of 147.5 ± 8 nm and PDI of 0.239 ± 0.03, respectively. The liposomes exhibited zeta potential of -27.6 ± 4.6 mV and spherical morphology. The Fourier transformed infrared (FTIR) spectroscopy and differential scanning calorimetry (DSC) revealed compatibility and thermal stability of the formulation components. Moreover, Powder X-ray diffraction (PXRD) studies signify the amorphous nature of extract following incorporation into liposomes. The antioxidant activity of extract and liposome was observed to be similar to ascorbic acid. Furthermore, significant phagocytic index was shown by both extract and liposome in rats, revealing their potent immunostimulant activity.</p><p><strong>Conclusions: </strong>Thus, <i>DC</i> extract-laden liposomes may serve as a promising immunostimulant, particularly in recurrent infections, immunodeficiencies, and recovery from chronic illness.</p>","PeriodicalId":11263,"journal":{"name":"Drug Development and Industrial Pharmacy","volume":" ","pages":"1273-1290"},"PeriodicalIF":2.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147722137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intranasal nanoemulsion-based <i>in-situ</i> gel containing dexlansoprazole: formulation development, <i>in-vitro</i> and <i>ex-vivo</i> evaluation.","authors":"Gyati Shilakari, Sai Kumar Uppala, Meghamala Ganti, Srilatha Bhukya, Abhay Asthana","doi":"10.1080/03639045.2026.2657498","DOIUrl":"10.1080/03639045.2026.2657498","url":null,"abstract":"<p><strong>Aim: </strong>Dexlansoprazole (DXL) is clinically effective in gastroesophageal reflux and ulcer healing, yet its oral bioavailability is compromised by acid instability, poor aqueous solubility, and extensive first-pass metabolism. To address these limitations, an intranasal nanoemulsion-based <i>in situ</i> gel was developed to bypass gastrointestinal and hepatic metabolism and enable rapid systemic absorption <i>via</i> the highly vascularized nasal mucosa. Owing to the BCS Class II nature of DXL, this approach was designed to enhance solubility, prolong nasal residence time, and provide sustained drug release.</p><p><strong>Methods: </strong>DXL-loaded nanoemulsions (NEs) were prepared using Capmul MCM EP as the oil phase, Cremophor EL as the surfactant, and PEG 300 as the co-surfactant by sonication. The NEs were evaluated for various <i>in vitro</i> parameters, <i>in vitro</i> drug release, and <i>ex vivo</i> permeation.</p><p><strong>Results: </strong>Among all NEs, F3 exhibited optimal characteristics, with a mean droplet size of 40.55 nm, a PDI of 0.374, a zeta potential of -17.70 mV, spherical globules under TEM and the highest cumulative release of 90.02% at 24 h. All NEs displayed significantly enhanced drug release as compared to the drug suspension. Cumulative drug permeation of 90.02 ± 0.565% for F3 and 80.69 ± 0.057% for its <i>in situ</i> gel (F3NEG4) was recorded, with 5.54- and 5.18-fold higher J_ss than the drug suspension, respectively. Additionally, F3 remained physically stable for 3 months at 2-8 °C and 25 ± 5 °C.</p><p><strong>Conclusion: </strong>The developed DXL-loaded NE improved <i>in vitro</i> dissolution, indicating potential enhancement of bioavailability, which requires confirmation through comprehensive <i>in vivo</i> studies.</p>","PeriodicalId":11263,"journal":{"name":"Drug Development and Industrial Pharmacy","volume":" ","pages":"1251-1272"},"PeriodicalIF":2.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147662412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Orodispersible tablets in psychiatric and mood disorder management: clinical value, pharmacokinetics, and patient-centric formulation strategies.","authors":"Govind Kumar, Ishu Garg, Rohit Raj, Balajee Soni, Nargis Saifi, Madhu Verma, Iti Chauhan","doi":"10.1080/03639045.2026.2673053","DOIUrl":"10.1080/03639045.2026.2673053","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the extensive literature underlying the concept of using and formulating Orodispersible tablets (ODTs) for managing psychiatric and mood disorders.</p><p><strong>Significance: </strong>Psychiatric and mood disorders represent a major global health burden across all age groups, significantly impairing quality of life and daily functioning. Emotional distress associated with these conditions often leads to poor medication adherence and difficulty swallowing, particularly in vulnerable populations. Thus, an increased emergency intervention is required during acute panic or agitation states. ODTs have emerged as a patient-oriented, rapidly disintegrating oral drug delivery system. It enhances treatment adherence and facilitates faster therapeutic action, especially during acute psychiatric episodes. ODTs offer distinct advantages for antipsychotics, antidepressants, anxiolytics, and mood stabilizers by modulating pharmacokinetic and pharmacodynamic profiles based on the drug's Biopharmaceutics Classification System (BCS).</p><p><strong>Key findings: </strong>Recent advances in three-dimensional (3D) printing, nanotechnology, and smart polymer systems have expanded the potential of ODTs. These technologies can effectively address key formulation challenges such as dose loading, poor solubility, moisture sensitivity, and taste masking, and ensure personalized dosing strategies. In parallel, the application of Quality by Design (QbD) and systematic optimization approaches allows the development of robust ODT formulations with adequate mechanical strength, rapid disintegration, and consistent performance.</p><p><strong>Conclusion: </strong>The rational development and clinical translation of tailored psychiatric ODTs for patients require adherence to established regulatory frameworks to ensure product quality, safety, efficacy, and patient acceptability.</p>","PeriodicalId":11263,"journal":{"name":"Drug Development and Industrial Pharmacy","volume":" ","pages":"1204-1219"},"PeriodicalIF":2.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147873626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polyherbal green-synthesised silver nanoparticle gel: in vitro antimicrobial activity and <i>in vivo</i> wound healing efficacy using mimosa pudica and tribulus terrestris extracts.","authors":"Purushotham C M, Mallamma T, Parimala Hanumesh, Jeevan Gowda, Rohith S, Prasiddhi Naik, Prakash Goudanavar","doi":"10.1080/03639045.2026.2668052","DOIUrl":"10.1080/03639045.2026.2668052","url":null,"abstract":"<p><strong>Objective: </strong>To synthesize and evaluate a polyherbal silver nanoparticle (PH-AgNPs) gel using <i>Mimosa pudica</i> and <i>Tribulus terrestris</i> extracts for enhanced antimicrobial activity and wound-healing efficacy.</p><p><strong>Significance: </strong>Wound infections remain a major clinical challenge due to rising antimicrobial resistance and cytotoxic limitations of conventional silver therapies. Green-synthesized PH-AgNPs offer a biocompatible and sustainable approach integrating antimicrobial and regenerative effects.</p><p><strong>Methods: </strong>PH-AgNPs were synthesized <i>via</i> green methods and characterized using UV-Vis, DLS, FTIR, XRD, and SEM-EDX. Nanoparticles were incorporated into Carbopol gels (0.1% and 0.2% w/w). Antioxidant activity was assessed by DPPH assay, antibacterial activity by agar well diffusion, and <i>in vivo</i> wound healing was evaluated using a full-thickness excision model in Wistar rats. Biochemical (CAT, glutathione peroxidase, lipid peroxidation) and histopathological analyses were performed, with AgNO₃ gel as standard.</p><p><strong>Results: </strong>The synthesized Silver Nanoparticles (AgNPs) exhibited a hydrodynamic diameter of 87 nm and a zeta potential of -25.4 mV. The polyherbal extract (PE) demonstrated 77.23% inhibition of DPPH radicals. Antibacterial testing showed inhibition zones of 14-15 mm against <i>Escherichia coli (E. Coli)</i> and <i>Staphylococcus aureus (S. aureus)</i>. Biochemical analysis showed differences in antioxidant enzyme activities, including CAT and glutathione peroxidase, between the treatment groups and the control. The 0.2% w/w AgNPs gel achieved 94.25% wound contraction by day 15 compared with 48.35% in untreated controls.</p><p><strong>Conclusion: </strong>PH-AgNPs gel exhibited effective antimicrobial activity and accelerated wound healing, suggesting potential as a safer alternative to conventional silver-based wound therapies.</p>","PeriodicalId":11263,"journal":{"name":"Drug Development and Industrial Pharmacy","volume":" ","pages":"1338-1356"},"PeriodicalIF":2.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147812407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving Paclitaxel permeation and anticancer efficacy through Soluplus-based solid dispersion with Piperine.","authors":"Riyad F Alzhrani, Syed Sarim Imam, Sultan Alshehri, Wael A Mahdi, Rawan A Fitaihi, Saad Alobid, Gamaleldin I Harisa","doi":"10.1080/03639045.2026.2675437","DOIUrl":"10.1080/03639045.2026.2675437","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to develop and optimize a Soluplus-based Paclitaxel-Piperine (PTX-PPN) solid dispersion to enhance PTX solubility, intestinal permeation, and anticancer efficacy in metastatic breast cancer cells.</p><p><strong>Significance: </strong>PTX suffers from extremely poor aqueous solubility and dose-limiting toxicity associated with Cremophor^® EL-based formulations. PPN is a well-documented bioenhancer and P-glycoprotein inhibitor that may modulate PTX permeation and cytotoxicity.</p><p><strong>Methods: </strong>PTX-PPN solid dispersions were prepared <i>via</i> freeze-drying using different PTX-PPN-Soluplus ratios (1:1:1, 1:1:1.5, and 1:1:2 w/w). The formulations were evaluated for drug content, saturation solubility, dissolution and solid-state characterization (FTIR, DSC, XRD, and microscopy). Intestinal permeation was assessed using an <i>ex vivo</i> model of intestinal permeation. Cytotoxicity and apoptosis were evaluated in 4T1 metastatic breast cancer cells.</p><p><strong>Results: </strong>The optimized PTX-PPN-Soluplus (1:1:1.5) formulation significantly enhanced solubility (PTX: 413.7 ± 36.7 µg/mL; PPN: 827.7 ± 38.7 µg/mL) compared to pure drugs. Solid-state analyses supported the conversion of pure PTX and PPN into an amorphous form. The incorporation of PPN into the PTX-Soluplus formulation significantly improved PTX permeation, resulting in 6-fold enhancement in flux compared with PTX alone. In 4T1 metastatic breast cancer cells, the co-loaded PTX-PPN-Soluplus solid dispersion (16 µM) displayed significantly higher cytotoxicity than PTX alone, reducing cell viability by 1.6-fold. Moreover, the PTX-PPN-Soluplus formulation induced apoptosis almost threefold higher than PTX-PPN alone.</p><p><strong>Conclusion: </strong>The developed PTX-PPN-Soluplus solid dispersion system represents a promising strategy to overcome PTX solubility limitations and support its broader clinical application in breast cancer therapy.</p>","PeriodicalId":11263,"journal":{"name":"Drug Development and Industrial Pharmacy","volume":" ","pages":"1391-1403"},"PeriodicalIF":2.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147980893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}